Atossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter ...
16 October 2017 - 11:00PM
Atossa Genetics (NASDAQ:ATOS), a clinical-stage
pharmaceutical company developing novel therapeutics and delivery
methods for breast cancer and other breast conditions, announced
today that the Ernest Mario School of Pharmacy at Rutgers, The
State University at New Jersey, plans to conduct a study utilizing
Atossa’s intraductal microcatheter technology.
The Rutgers researchers believe that directly administering
drugs into the breast duct where breast cancer grows, by inserting
microcatheters into the nipple, is a better alternative than
systemic administration, because the drugs will be directly
delivered to the tissue. The Rutgers program uses a unique directed
delivery system comprised of nanoscale pharmaceutical carriers
loaded with single drugs. The long-term goal of the research
program is to develop a locally administered drug delivery system
that selectively targets and delivers pathway-specific targeting
therapeutics to eliminate breast cancer cells and cancer stem-like
cells while sparing normal breast cells.
“We are encouraged that a leading research institution like
Rutgers recognizes the potential merit of our microcatheter
technology. Atossa fully supports additional research utilizing our
patented microcatheter technology,” stated Steven Quay, MD, PhD,
Atossa CEO and President.
The Rutgers program is in the research and development phase and
has not been approved by the FDA or any other regulatory body.
Studies demonstrating safety and efficacy, among other things, and
regulatory approvals will be required before commercialization.
About Atossa Genetics
Atossa Genetics Inc., is a clinical-stage pharmaceutical company
developing novel therapeutics and delivery methods to treat breast
cancer and other breast conditions. For more information, please
visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa, lower than anticipated rate of patient enrollment, results
of clinical studies, the safety and efficacy of Atossa's products
and services, performance of clinical research organizations and
investigators, obstacles resulting from proprietary rights held by
others, such as patent rights, and other risks detailed from time
to time in Atossa's filings with the Securities and Exchange
Commission, including without limitation its periodic reports on
Form 10-K and 10-Q, each as amended and supplemented from time to
time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.Kyle GuseCFO and General Counsel866
893-4927kyle.guse@atossagenetics.com
Investor Relations Contact
Scott GordonCorProminence LLC377 Oak StreetConcourse 2Garden
City, NY 11530Office:
516.222.2560scottg@corprominence.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024